Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

CVS sees 23% revenue growth in healthcare benefits & projects 10% EPS in 2025, with Aetna recovery boosting performance.

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...